ACAD Acadia Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

$20.39  -0.29 (-1.40%)
As of 04/09/2021 15:59:57 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/27/2004
Outstanding shares:  160,047,470
Average volume:  3,080,531
Market cap:   $3,263,367,913
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    004225108
ISIN:        US0042251084
Sedol:      2713317
Valuation   (See tab for details)
PE ratio:   -11.59
PB ratio:   5.19
PS ratio:   7.39
Return on equity:   -44.91%
Net income %:   -63.74%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy